title: Tyrosine kinase inhibitors target cancer stem cells in renal cell cancer.
abstract: This study was designed to analyze the impact of multi-targeted tyrosine kinase inhibitors on the cancer stem cell subpopulation in renal cell cancer. The second objective was to evaluate the effect of tumor growth inhibition related to a tumor niche factor - oxygen deprivation - as hypoxia develops along with the anti-angiogenic activity of tyrosine kinase inhibitors in renal tumors. Cells were treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, in 2D and 3D culture conditions. Cell proliferation along with drug toxicity were evaluated. It was shown that the proliferation rate of cancer stem cells was decreased by the tyrosine kinase inhibitors. The efficacy of the growth inhibition was limited by hypoxic conditions and 3D intratumoral cell-cell interactions. We conclude that understanding the complex molecular interaction feedback loops between differentiated cancer cells, cancer stem cells and the tumor microenvironment in 3D culture should aid the identification of novel treatment targets and to evalute the efficacy of renal cancer therapies. Cell-cell interaction may represent a critical microenvironmental factor regulating cancer stem cell self-renewal potential, enhancing the stem cell phenotype and limiting drug toxicity. At the same time the role of hypoxia in renal cancer stem cell biology is also significant.
authors.affiliation: Laboratory of Molecular Oncology, Department of Oncology, Military Institute of Medicine, 04-141 Warsaw, Poland.
authors.forename: Anna M
authors.initials: AM
authors.lastname: Czarnecka
authors.affiliation: Laboratory of Molecular Oncology, Department of Oncology, Military Institute of Medicine, 04-141 Warsaw, Poland.
authors.forename: Wojciech
authors.initials: W
authors.lastname: Solarek
authors.affiliation: Laboratory of Molecular Oncology, Department of Oncology, Military Institute of Medicine, 04-141 Warsaw, Poland.
authors.forename: Anna
authors.initials: A
authors.lastname: Kornakiewicz
authors.affiliation: Laboratory of Molecular Oncology, Department of Oncology, Military Institute of Medicine, 04-141 Warsaw, Poland.
authors.forename: Cezary
authors.initials: C
authors.lastname: Szczylik
mesh_terms: D000077784:Axitinib; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D002450:Cell Communication / Q000187:drug effects*; D015687:Cell Hypoxia / Q000235:genetics; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage; D007191:Indazoles / Q000008:administration & dosage; D007211:Indoles / Q000008:administration & dosage; D014411:Neoplastic Stem Cells / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D009536:Niacinamide / Q000008:administration & dosage / Q000031:analogs & derivatives; D010100:Oxygen / Q000378:metabolism; D010671:Phenylurea Compounds / Q000008:administration & dosage; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage*; D011758:Pyrroles / Q000008:administration & dosage; D000077157:Sorafenib; D000077210:Sunitinib; D059016:Tumor Microenvironment / Q000187:drug effects*
chemical_list: D007093:Imidazoles; D007191:Indazoles; D007211:Indoles; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011758:Pyrroles; D009536:Niacinamide; D000077157:Sorafenib; D000077784:Axitinib; D010100:Oxygen; D000077210:Sunitinib